{ "meta": { "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.", "terms": "https://open.fda.gov/terms/", "license": "https://open.fda.gov/license/", "last_updated": "2026-04-28", "results": { "skip": 0, "limit": 1, "total": 36317 } }, "results": [ { "safetyreportversion": "2", "safetyreportid": "10003633", "primarysourcecountry": "US", "occurcountry": "US", "transmissiondateformat": "102", "transmissiondate": "20141002", "reporttype": "1", "serious": "1", "seriousnessdeath": "1", "receivedateformat": "102", "receivedate": "20140312", "receiptdateformat": "102", "receiptdate": "20140312", "fulfillexpeditecriteria": "1", "companynumb": "US-GE HEALTHCARE MEDICAL DIAGNOSTICS-OSCN-PR-1006S-0175", "duplicate": "1", "reportduplicate": { "duplicatesource": "GE HEALTHCARE", "duplicatenumb": "US-GE HEALTHCARE MEDICAL DIAGNOSTICS-OSCN-PR-1006S-0175" }, "primarysource": { "reportercountry": "US", "qualification": "4" }, "sender": { "sendertype": "2", "senderorganization": "FDA-Public Use" }, "receiver": { "receivertype": "6", "receiverorganization": "FDA" }, "patient": { "patientonsetage": "70", "patientonsetageunit": "801", "patientweight": "55.39", "patientsex": "1", "reaction": [ { "reactionmeddraversionpt": "17.0", "reactionmeddrapt": "Nephrogenic systemic fibrosis", "reactionoutcome": "5" } ], "drug": [ { "drugcharacterization": "1", "medicinalproduct": "OMNISCAN", "drugauthorizationnumb": "020123", "drugstructuredosagenumb": "40", "drugstructuredosageunit": "012", "drugdosageform": "SOLUTION FOR INJECTION", "drugadministrationroute": "042", "drugindication": "CEREBROVASCULAR ACCIDENT", "drugstartdateformat": "102", "drugstartdate": "20031122", "drugenddateformat": "102", "drugenddate": "20031122", "openfda": { "application_number": [ "NDA020123" ], "brand_name": [ "OMNISCAN" ], "generic_name": [ "GADODIAMIDE" ], "manufacturer_name": [ "GE Healthcare Inc." ], "product_ndc": [ "0407-0690" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "GADODIAMIDE" ], "spl_id": [ "dfe2f58c-7a8f-408a-9690-6300a49eda17" ], "spl_set_id": [ "1e9a37e2-f28a-4373-bf0f-3e9b60f42d8a" ], "package_ndc": [ "0407-0690-05", "0407-0690-10", "0407-0690-15", "0407-0690-20", "0407-0690-12", "0407-0690-17", "0407-0690-22" ], "nui": [ "N0000175862", "N0000180184" ], "pharm_class_moa": [ "Magnetic Resonance Contrast Activity [MoA]" ], "pharm_class_epc": [ "Paramagnetic Contrast Agent [EPC]" ], "unii": [ "84F6U3J2R6" ] } }, { "drugcharacterization": "1", "medicinalproduct": "OMNISCAN", "drugauthorizationnumb": "020123", "drugstructuredosagenumb": "40", "drugstructuredosageunit": "012", "drugdosageform": "SOLUTION FOR INJECTION", "drugadministrationroute": "042", "drugindication": "HYPERTENSION", "drugstartdateformat": "102", "drugstartdate": "20031123", "drugenddateformat": "102", "drugenddate": "20031123", "openfda": { "application_number": [ "NDA020123" ], "brand_name": [ "OMNISCAN" ], "generic_name": [ "GADODIAMIDE" ], "manufacturer_name": [ "GE Healthcare Inc." ], "product_ndc": [ "0407-0690" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "GADODIAMIDE" ], "spl_id": [ "dfe2f58c-7a8f-408a-9690-6300a49eda17" ], "spl_set_id": [ "1e9a37e2-f28a-4373-bf0f-3e9b60f42d8a" ], "package_ndc": [ "0407-0690-05", "0407-0690-10", "0407-0690-15", "0407-0690-20", "0407-0690-12", "0407-0690-17", "0407-0690-22" ], "nui": [ "N0000175862", "N0000180184" ], "pharm_class_moa": [ "Magnetic Resonance Contrast Activity [MoA]" ], "pharm_class_epc": [ "Paramagnetic Contrast Agent [EPC]" ], "unii": [ "84F6U3J2R6" ] } }, { "drugcharacterization": "1", "medicinalproduct": "OMNISCAN", "drugauthorizationnumb": "020123", "drugdosageform": "SOLUTION FOR INJECTION", "drugadministrationroute": "042", "drugindication": "RENAL ARTERY STENOSIS", "drugstartdateformat": "102", "drugstartdate": "20050326", "drugenddateformat": "102", "drugenddate": "20050326", "openfda": { "application_number": [ "NDA020123" ], "brand_name": [ "OMNISCAN" ], "generic_name": [ "GADODIAMIDE" ], "manufacturer_name": [ "GE Healthcare Inc." ], "product_ndc": [ "0407-0690" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "GADODIAMIDE" ], "spl_id": [ "dfe2f58c-7a8f-408a-9690-6300a49eda17" ], "spl_set_id": [ "1e9a37e2-f28a-4373-bf0f-3e9b60f42d8a" ], "package_ndc": [ "0407-0690-05", "0407-0690-10", "0407-0690-15", "0407-0690-20", "0407-0690-12", "0407-0690-17", "0407-0690-22" ], "nui": [ "N0000175862", "N0000180184" ], "pharm_class_moa": [ "Magnetic Resonance Contrast Activity [MoA]" ], "pharm_class_epc": [ "Paramagnetic Contrast Agent [EPC]" ], "unii": [ "84F6U3J2R6" ] } }, { "drugcharacterization": "1", "medicinalproduct": "OMNISCAN", "drugauthorizationnumb": "020123", "drugdosageform": "SOLUTION FOR INJECTION", "drugadministrationroute": "042", "drugindication": "PAIN IN EXTREMITY", "drugstartdateformat": "102", "drugstartdate": "20050428", "drugenddateformat": "102", "drugenddate": "20050428", "openfda": { "application_number": [ "NDA020123" ], "brand_name": [ "OMNISCAN" ], "generic_name": [ "GADODIAMIDE" ], "manufacturer_name": [ "GE Healthcare Inc." ], "product_ndc": [ "0407-0690" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "GADODIAMIDE" ], "spl_id": [ "dfe2f58c-7a8f-408a-9690-6300a49eda17" ], "spl_set_id": [ "1e9a37e2-f28a-4373-bf0f-3e9b60f42d8a" ], "package_ndc": [ "0407-0690-05", "0407-0690-10", "0407-0690-15", "0407-0690-20", "0407-0690-12", "0407-0690-17", "0407-0690-22" ], "nui": [ "N0000175862", "N0000180184" ], "pharm_class_moa": [ "Magnetic Resonance Contrast Activity [MoA]" ], "pharm_class_epc": [ "Paramagnetic Contrast Agent [EPC]" ], "unii": [ "84F6U3J2R6" ] } }, { "drugcharacterization": "2", "medicinalproduct": "OXYCONTIN", "drugindication": "PAIN", "openfda": { "application_number": [ "NDA022272" ], "brand_name": [ "OXYCONTIN" ], "generic_name": [ "OXYCODONE HYDROCHLORIDE" ], "manufacturer_name": [ "Knoa Pharma LLC" ], "product_ndc": [ "59011-410", "59011-415", "59011-420", "59011-430", "59011-440", "59011-460", "59011-480" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OXYCODONE HYDROCHLORIDE" ], "rxcui": [ "1049504", "1049545", "1049565", "1049576", "1049586", "1049595", "1049601", "1860127", "1860129", "1860137", "1860148", "1860151", "1860154", "1860157" ], "spl_id": [ "4a1edd18-f1f0-4609-9eaf-29067937c3c6" ], "spl_set_id": [ "bfdfe235-d717-4855-a3c8-a13d26dadede" ], "package_ndc": [ "59011-410-10", "59011-410-20", "59011-415-10", "59011-415-20", "59011-420-10", "59011-420-20", "59011-430-10", "59011-430-20", "59011-440-10", "59011-440-20", "59011-460-10", "59011-460-20", "59011-480-20", "59011-480-10" ], "unii": [ "C1ENJ2TE6C" ] } }, { "drugcharacterization": "2", "medicinalproduct": "NEURONTIN", "openfda": { "application_number": [ "NDA020882", "NDA020235", "NDA021129" ], "brand_name": [ "NEURONTIN" ], "generic_name": [ "GABAPENTIN" ], "manufacturer_name": [ "Parke-Davis Div of Pfizer Inc", "Viatris Specialty LLC" ], "product_ndc": [ "0071-0401", "0071-0803", "0071-0805", "0071-0806", "0071-0513", "0071-2012", "58151-281", "58151-282", "58151-283", "58151-284", "58151-285", "58151-290" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "GABAPENTIN" ], "rxcui": [ "105028", "105029", "105030", "261280", "261281", "283523", "310430", "310431", "310432", "310433", "310434", "351973" ], "spl_id": [ "e730d5df-d47b-4d7f-ae3b-bd449f6b1213", "dfbc1443-0ba8-479b-8590-32bd942732d4" ], "spl_set_id": [ "ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388", "97935fd9-1d4a-43b6-a5d9-de994591187b" ], "package_ndc": [ "0071-0803-24", "0071-0803-40", "0071-0805-24", "0071-0805-40", "0071-0806-24", "0071-0806-40", "0071-0513-24", "0071-0401-24", "0071-2012-23", "0071-2012-44", "0071-2012-47", "58151-281-01", "58151-282-01", "58151-283-01", "58151-284-01", "58151-285-01", "58151-290-35" ], "nui": [ "N0000008486" ], "pharm_class_pe": [ "Decreased Central Nervous System Disorganized Electrical Activity [PE]" ], "unii": [ "6CW7F3G59X" ] } }, { "drugcharacterization": "2", "medicinalproduct": "THALIDOMIDE", "drugindication": "NEPHROGENIC SYSTEMIC FIBROSIS", "drugstartdateformat": "102", "drugstartdate": "20050823", "openfda": { "application_number": [ "NDA020785" ], "brand_name": [ "THALOMID" ], "generic_name": [ "THALIDOMIDE" ], "manufacturer_name": [ "Celgene Corporation" ], "product_ndc": [ "59572-205", "59572-210", "59572-215", "59572-220" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "THALIDOMIDE" ], "rxcui": [ "200390", "213360", "360176", "360177", "404449", "404450", "700416", "700418" ], "spl_id": [ "58b287d1-24f5-4dfe-84ca-898a8a5b9302" ], "spl_set_id": [ "2eda833b-1357-4ed4-a093-194524fcb061" ], "package_ndc": [ "59572-205-14", "59572-205-94", "59572-205-17", "59572-205-97", "59572-210-15", "59572-210-95", "59572-215-13", "59572-215-93", "59572-220-16", "59572-220-96" ], "nui": [ "N0000008663" ], "pharm_class_pe": [ "Decreased Immunologically Active Molecule Activity [PE]" ], "unii": [ "4Z8R6ORS6L" ] } }, { "drugcharacterization": "2", "medicinalproduct": "CELEXA", "drugindication": "PAIN", "openfda": { "application_number": [ "NDA020822" ], "brand_name": [ "CELEXA" ], "generic_name": [ "CITALOPRAM" ], "manufacturer_name": [ "Allergan, Inc." ], "product_ndc": [ "0456-4010", "0456-4020", "0456-4040" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CITALOPRAM HYDROBROMIDE" ], "rxcui": [ "200371", "213344", "213345", "283672", "284591", "309314" ], "spl_id": [ "0eee9751-8886-474c-a806-8003e90cb151" ], "spl_set_id": [ "4259d9b1-de34-43a4-85a8-41dd214e9177" ], "package_ndc": [ "0456-4010-01", "0456-4020-01", "0456-4020-11", "0456-4020-63", "0456-4040-01", "0456-4040-11", "0456-4040-63" ], "unii": [ "I1E9D14F36" ] } }, { "drugcharacterization": "2", "medicinalproduct": "INTRAVENOUS IMMUNOGLOBULIN", "drugindication": "NEPHROGENIC SYSTEMIC FIBROSIS", "drugstartdateformat": "102", "drugstartdate": "20050808" }, { "drugcharacterization": "2", "medicinalproduct": "OXYCODONE", "drugindication": "PAIN", "openfda": { "application_number": [ "ANDA203638", "NDA208090" ], "brand_name": [ "OXYCODONE HYDROCHLORIDE", "XTAMPZA ER" ], "generic_name": [ "OXYCODONE" ], "manufacturer_name": [ "Amneal Pharmaceuticals LLC", "Collegium Pharmaceutical, Inc." ], "product_ndc": [ "65162-047", "65162-048", "65162-049", "65162-050", "65162-051", "24510-110", "24510-115", "24510-120", "24510-130", "24510-140" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OXYCODONE HYDROCHLORIDE", "OXYCODONE" ], "rxcui": [ "1049611", "1049618", "1049621", "1049683", "1049686", "1790527", "1790533", "1791558", "1791560", "1791567", "1791569", "1791574", "1791576", "1791580", "1791582" ], "spl_id": [ "8b9e3253-7735-44cc-a59b-3125ab573c84", "fda0989d-9319-4e35-af83-fca1ec66878e" ], "spl_set_id": [ "094b64b3-cd32-4de5-afb6-ea00d9caad74", "b0a5ded2-8ee2-49ca-a86c-2b28ae40f60c" ], "package_ndc": [ "65162-047-03", "65162-047-10", "65162-047-25", "65162-047-50", "65162-048-03", "65162-048-10", "65162-048-25", "65162-049-03", "65162-049-10", "65162-049-25", "65162-049-50", "65162-050-03", "65162-050-10", "65162-050-25", "65162-051-03", "65162-051-10", "65162-051-25", "65162-051-50", "24510-110-10", "24510-110-20", "24510-115-10", "24510-115-20", "24510-120-10", "24510-120-20", "24510-130-10", "24510-130-20", "24510-140-10", "24510-140-20" ], "unii": [ "C1ENJ2TE6C", "CD35PMG570" ], "nui": [ "N0000175684", "N0000175690" ], "pharm_class_moa": [ "Full Opioid Agonists [MoA]" ], "pharm_class_epc": [ "Opioid Agonist [EPC]" ] } } ] } } ] }